Navigation Links
Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, announced today that it has started testing its lead product, Hemospan(R), in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients.

The single-blind, placebo-controlled study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and efficacy of Hemospan in patients suffering from CCLI, a debilitating condition that results from severely limited blood circulation to the legs. The primary endpoint is tissue oxygenation measured noninvasively.

The goal of this study is to demonstrate that Hemospan can increase oxygen supply to severely compromised tissue, conclusively establishing it as an 'oxygen-carrying plasma expander,'" said Dr. Robert Winslow, Chairman, President and CEO of Sangart.

Hemospan is a hemoglobin-based oxygen transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.

About Sangart

Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as oxygen transport agents.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow's group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. Fro
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
2. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
3. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
4. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
5. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
6. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
7. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
11. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 RadiologyAuction will have their first auction starting ... demonstrations at the end of the auction on May ... and Fuji Cr,s, Agfa and Sony, printers and GE ... Various imaging equipment will be available at later auctions ... years of buying and selling imaging equipment, the brokers ...
(Date:5/4/2015)... , May 4, 2015 PharmaEngine, ... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) with ... BAX ) jointly announced that Baxter has submitted ... Medicines Agency (EMA) for MM-398 (irinotecan liposome injection), ... adenocarcinoma of the pancreas who have been previously ...
(Date:5/4/2015)... May 4, 2015  Makindus, Inc. a specialty pharmaceutical ... European Medicines Agency (EMA) has granted orphan drug designation ... Stargardt,s Disease. "We are extremely pleased to ... Stargardt,s disease in place for Europe ... the United States for which ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2
... GRASS VALLEY, Calif., Jan. 18, 2011 Eigen, a ... announced the completion of the company,s restructuring plan designed ... billion urology medical device marketplace. The company ... is now positioned with a unified management team and ...
... 2011 Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: ... today announced financial results of the three months ended ... the noninvasive treatment of cardiovascular diseases. In addition, the ... VasoHealthcare , commenced operations on July 1, 2010 under ...
Cached Medicine Technology:Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 3Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 4
(Date:5/5/2015)... (PRWEB) May 05, 2015 The ... for assessing and treating children with feeding and ... the course of 20 years through the clinical ... Kay Toomey , in conjunction with colleagues from ... dieticians, and speech pathologists. Education Resources Inc. is ...
(Date:5/5/2015)... NJ (PRWEB) May 05, 2015 Texting has ... is no surprise that some physicians text as a way ... we urge providers who are doing so to assure medical ... does not come without risk! When providers transmit protected ... mobile devices, they run the risk of violating the Health ...
(Date:5/5/2015)... Curly Hair Solutions™ is delighted to introduce the ... Mist. The collection has every curl type covered, ... loose to medium body curls is exposure to the ocean ... fancying the ocean breeze needn’t leave their bathroom. , ... Mist produces the same invigorating freshness one gets when exposed ...
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 Lauren ... goods retailer City Sports , was named one ... and active lifestyle industry by the SportsOneSource ... , Ms. Blanda, 33, is one of 40 executives ... Sporting Goods Business magazine) recognized for exceptional achievement in ...
(Date:5/4/2015)... Parlin dentist, Dr Mariana Blagoev is extending her ... to participate and win a laptop. , Dr. Blagoev created ... good deeds and share them on her Facebook page. By ... teach them to be kind and compassionate when they mature ... years of age and under. Youths are urged to submit ...
Breaking Medicine News(10 mins):Health News:Commission on Dietetic Registration Approves Two Pediatric Feeding Courses Offered by Education Resources Inc. 2Health News:HIPAA Compliant Texting Service from MedXcom now available for Policyholders 2Health News:Curly Hair Solutions Introduces New Revolutionary Product: Curl Keeper Beach Mist 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 2Health News:Sporting Goods Trade Group Names City Sports’ Lauren Blanda to Its Annual “40 Under 40” List 3Health News:10 More Days To Enter Good Deed Contest 2
... a connection with obesity risks as they grow up, more so, in ... team of researchers led by Sarah E. Anderson, M.S., from Tufts University ... and 417 men - who underwent assessment four times between 1983 and ... during the beginning of the study, and were in the age group ...
... deteriorate as they progress through puberty, reveals a new ... levels of insulin, however, remain unchanged in their Caucasian ... plays a crucial role in determining the individual risk ... study was conducted by Dr. Geoff Ball and his ...
... Ramadoss said that India is crowned as the diabetic capital. ... national programme for prevention and control of cardiovascular disease, //stroke ... meeting. ,He submitted a draft of the programme ... to make it workable. ,The programme’s main ...
... global network of virus, spyware and spam analysis centers, have warned ... across the internet.// ,This letter claims that lipstick causes ... contain a dangerously high level of lead which can cause cancer. ... claims are not true. ,Sopho has asked the users ...
... incidence of pregnancy complications, more specifically preeclampsia related//, ... Obstetrics and Gynecology. ,Preeclampsia, a pregnancy-related ... (high levels of protein in the urine). Swelling ... seen. If left unattended, the condition can worsen ...
... the women especially the pregnant women about the risks ... as selective serotonin re-uptake inhibitors //(SSRIs) affect the fetus. ... called persistent pulmonary hypertension in babies born to women ... The recent study links SSRIs to this fatal condition ...
Cached Medicine News:Health News:African American Children More Pone to Develop Diabetes 2
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
... provides 5% povidone-iodine solution ... It delivers a microbicidal ... tender to touch. It ... indicated whenever effective microbicidal ...
Medicine Products: